Nov142019 Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome November 14, 2019
Nov62019 Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome November 6, 2019
Oct92019 Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Oct22019 Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease October 2, 2019
Sep272019 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study September 27, 2019
Sep262019 Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference September 26, 2019
Sep182019 Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference September 18, 2019
Sep162019 Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome September 16, 2019
Sep42019 Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome September 4, 2019
Aug72019 Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study Updates August 7, 2019
Aug22019 Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019 August 2, 2019
